Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,950 | 2 | 98.2% |
| Education | $47.52 | 1 | 1.6% |
| Food and Beverage | $6.00 | 2 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $2,956 | 4 | $0 (2024) |
| CSL Behring | $47.52 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6.00 | 2 | PFIZER INC. ($6.00) |
| 2022 | $2,950 | 2 | PFIZER INC. ($2,950) |
| 2018 | $47.52 | 1 | CSL Behring ($47.52) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/08/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $3.18 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/01/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $2.82 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/29/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/17/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $2,025.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/28/2018 | CSL Behring | Hizentra (Biological) | Education | In-kind items and services | $47.52 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA | PFIZER INC. | $2,950 | 2 |
About Dr. Dawn Wahezi, M.D
Dr. Dawn Wahezi, M.D is a Pediatrics healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/08/2009. The National Provider Identifier (NPI) number assigned to this provider is 1518290725.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dawn Wahezi, M.D has received a total of $3,004 in payments from pharmaceutical and medical device companies, with $6.00 received in 2024. These payments were reported across 5 transactions from 2 companies. The most common payment nature is "" ($2,950).
Practice Information
- Specialty Pediatrics
- Location Bronx, NY
- Active Since 09/08/2009
- Last Updated 09/08/2009
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1518290725
Products in Payments
- XELJANZ (Drug) $2,956
- Hizentra (Biological) $47.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Bronx
Philip Ozuah, Md, MD
Pediatrics — Payments: $1.0M
Dr. Giancarlo Guido, M.d, M.D
Pediatrics — Payments: $107,731
Dr. Bryan Rudolph, Md, Mph, MD, MPH
Pediatrics — Payments: $104,918
Jennifer Davila, Md, MD
Pediatrics — Payments: $95,463
Acklema Mohammad, Md, MD
Pediatrics — Payments: $37,568
Solomon Moshe, Md, MD
Pediatrics — Payments: $26,472